Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review

被引：7

作者：

Wu, Jinchun ^{[1
]}

Liu, Yanmin ^{[1
]}

Wei, Xiaojuan ^{[1
]}

Zhang, Xiaofei ^{[1
]}

Ye, Yi ^{[2
]}

Li, Wei ^{[1
]}

Su, Xiaoling ^{[1
]}

机构：

[1] Qinghai Prov Peoples Hosp, Dept Cardiol, Xining, Peoples R China

[2] Qinghai Univ, Grad Sch, Xining, Peoples R China

来源：

FRONTIERS IN CARDIOVASCULAR MEDICINE | 2022年 / 9卷

关键词：

Na+ homeostasis; Ca2+ homeostasis; Na+-H+ exchanger regulatory factor (NHERF)1; 2; Na+-Ca2+ exchanger (NCX); ventricular arrhythmia (VAs); atrial fibrillation; arrhythmia; sodium-glucose cotransporter 2 inhibitor; SUDDEN CARDIAC DEATH; SGLT2; INHIBITORS; HEART-FAILURE; VENTRICULAR-ARRHYTHMIAS; DIASTOLIC DYSFUNCTION; ATRIAL-FIBRILLATION; ARTERIAL STIFFNESS; NA+/H+ EXCHANGER; BLOOD-PRESSURE; EMPAGLIFLOZIN;

D O I：

10.3389/fcvm.2022.915455

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new type of oral hypoglycaemic agent with good cardiovascular protective effects. There are several lines of clinical evidence suggest that SGLT2i can significantly reduce the risks of heart failure, cardiovascular death, and delay the progression of chronic kidney disease. In addition, recent basic and clinical studies have also reported that SGLT2i also has good anti-arrhythmic effects. However, the exact mechanism is poorly understood. The aim of this review is to summarize recent clinical findings, studies of laboratory animals, and related study about this aspect of the antiarrhythmic effects of SGLT2i, to further explore its underlying mechanisms, safety, and prospects for clinical applications of it.

引用

页数：10

共 50 条

[41] Gout and sodium-glucose cotransporter-2 inhibitors
Lai, Shih-Wei
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 (01) : 112 - 113
[42] The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)-A Narrative Review
Iordan, Liana
Gaita, Laura
Timar, Romulus
Avram, Vlad
Sturza, Adrian
Timar, Bogdan
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (13)
[43] Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control
Takata, Tomoaki
Isomoto, Hajime
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
[44] Sodium-glucose cotransporter 2 inhibitors: A comprehensive review from cells to bedside
Bagheri, Bahador
Yaribeygi, Habib
Taherifard, Erfan
Talasaz, Azita Hajhossein
Bagheri, Haleh
Darban, Mahboubeh
Tabrizi, Reza
Najafi, Siamak
Khodadost, Mahmoud
Akbari, Maryam
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 (03) : 481 - 492
[45] Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review
Dubrofsky, Lisa
Srivastava, Anand
Cherney, David Z.
CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE, 2020, 7
[46] Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
Lei Xiao
Xin Nie
Yanyan Cheng
Nanping Wang
Cardiovascular Drugs and Therapy, 2021, 35 : 1253 - 1267
[47] Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors
Chiriaco, Martina
Trico, Domenico
Solini, Anna
CURRENT OPINION IN PHARMACOLOGY, 2022, 66
[48] Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
Koh, Eun Sil
Kim, Gheun-Ho
Chung, Sungjin
ENDOCRINOLOGY AND METABOLISM, 2023, 38 (04) : 359 - 372
[49] Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors
Verma, Subodh
Mudaliar, Sunder
Greasley, Peter J.
ADVANCES IN THERAPY, 2024, 41 (01) : 92 - 112
[50] Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors
Yanai, Hidekatsu
CARDIOLOGY RESEARCH, 2021, 12 (05) : 324 - 326

← 1 2 3 4 5 →